#bcg vaccine trial

[bpod-bpod]

Frozen Out

Developed just over a hundred years ago, the BCG vaccine is the only vaccine widely-used against tuberculosis, or TB, a disease caused by infection with Mycobacterium tuberculosis (Mtb, pictured). While highly effective in protecting infants from the most serious forms of disease, BCG is less successful in preventing transmission and lung disease in adults. TB remains one of the deadliest infectious diseases worldwide, with most cases in South-East Asia and Africa. New vaccines are being tested, including promising solutions combining antigens, molecules provoking an immune response specifically against Mtb, with adjuvants, that further stimulate the immune system. In recent phase I clinical trials, a freeze-dried vaccine, that would not need to be kept refrigerated, was found to be safe, causing no serious side-effects, and to trigger antibody production. While still in early stages of testing, a more robust vaccine would be hugely beneficial to vaccination campaigns in remote areas.

Written by Emmanuelle Briolat

Image from the NIH, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda MD, USA

Research from Zachary K. Sagawa et al, Access to Advanced Health Institute (formerly Infectious Disease Research Institute), Seattle, WA, USA

Image in the Public Domain

Research published in Nature Communications, March 2023

You can also follow BPoD on Instagram, Twitter and Facebook

[stuckonaglacierwithmacgyver]

I present for your consideration, some of the human trials they 'just did':

Nutrition experiments carried out on Canadian Aboriginal children in residential schools between 1942 and 1952, in which various control and experimental groups were deliberately malnourished. Also the Qu'Appelle BCG vaccine trial.

Basically everything the Australian government has done to the Aboriginal people, but especially experiments in the 20s and 30s, which tested basal metabolism by forcing subjects to lie still and breath through a rubber tube for hours, or those testing their response to pain.

Testing of a new antibiotic* on children in Kano, Nigeria, during a meningococcal meningitis outbreak, by Pfizer. The lawsuit the families and the Nigerian government brought against Pfizer also alleged that this further reduced the public's trust in vaccines and contributed to poor uptake of the polio vaccine.

The Tuskeegee Syphillis Study, which is a landmark in medical ethics fuckery that everyone should know about. The US has also carried out variations of this in so many places

Southam's experiments on prisoners using HeLa cancer cells** without their informed consent.

The Rawalpindi experiments carried out on members of the British Indian army to test mustard gas.

I'm not even going to talk about the Nazi ones.

*In this case they actually did do animal trials beforehand, which contraindicated its use in children, but I included this because it demonstrates how unethical research practice can impact public health.

**HeLa cells in themselves are also a colossal fuckup of informed consent!

the cognitive dissonance from people who want the products of modern medicine but get weird about animal research. like im sorry but this is necessary for the survival of the society we currently live in. and the scientists who work on these things are not evil cackling psychopaths. anyone you talk to in animal research has incredibly complex feelings about their work and incredibly complex relationships to the animals in their care. there are regulations and oversight and penalties in place to make the work as humane as possible and scientists are overwhelmingly the ones enforcing and advocating for better care.

[ramtracking]

Clinical trials of first adult TB vaccine derived from human source begins [ BCG vaccine ]

Clinical trials of first adult TB vaccine derived from human source begins [News Summary] Bharat Biotech International Limited, in collaboration with Biofabri, has started a series of clinical trials in adults in the country to… India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world’s first Mycobacterium… World Tuberculosis (TB) Day is marked…

[decentralvaccine]

Clinical Trials Begin For Spanish TB Vaccine

Clinical trials of Spanish tuberculosis (TB) vaccine MTBVAC have begun in India.

Vaccine maker Bharat Biotech is conducting the trials in partnership with Spanish biopharmaceutical company Biofabri that is responsible for clinical and industrial development of the vaccine developed in the laboratory of the University of Zaragoza with Dr. Brigitte Gicquel of the Pasteur Institute, Paris.

MTBVAC is the only vaccine against tuberculosis in clinical trials based on a genetically modified form of the pathogen isolated from humans Mycobacterium tuberculosis which, unlike the BCG vaccine, contains all the antigens present in strains that infect humans. While the trials to evaluate the safety and immunogenicity of MTBVAC in India have begun, a pivotal safety, immunogenicity and efficacy trial is planned in 2025, Bharat Biotech said in an announcement coinciding with World Tuberculosis Day on March 24.

[gobeautifulnerdbouquetlove]

BMC initiative | A vaccine trial to prevent TB: Adults to get BCG jab starting May - The Indian Express

http://dlvr.it/T4TyNp

[tis-i-espresso-magpie]

that is the PPD test yeah! the PPD stands for purified protein derivative, and it’s also called the tuberculin skin test/tuberculin sensitivity test (TST) or the mantoux test, and it’s of the most common ways to screen for TB, especially in countries that don’t have a lot of it

there are also testing cartridges made by the company cepheid that are used in countries with high TB burdens, and they are literally described by health care professionals as "revolutionary" and "miraculous". in just 2 hours, it can check for both TB and specific antibiotic resistances (drug resistance is a very big problem with tuberculosis). the standard test (Xpert MTB/RIF) checks for both the infection and resistance to rifampin (that’s one of the most common first-line antibiotics used to treat TB), and if you’re positive with TB then you’re supposed to* receive another test (Xpert MTB/XDR), (the XDR stands for "extensively drug-resistant") which screens resistance to 9 other antibiotics

if you’re in the US, you probably haven’t received a tuberculosis vaccine actually. the US has never required it and it’s very rarely given there (my family is from southern canada and we’re non-native, so i and my siblings never got it but our parents did). the efficacy of the BCG is very debated (i have to clarify this isn’t an anti-vax position or anything, there are other vaccines in development for TB that look better (especially one called MTBVAC, which looks very promising and is in phase 3 clinical trials right now!) and i’m hoping they turn out well and are approved for use quickly)

the BCG vaccine is also kind of notorious for causing false positives of LTBI (latent tuberculosis infections) on the tuberculin skin test (that’s the PPD test you received!) the US officially says that prior BCG vaccination should not influence the interpretation of the test, and this probably results in a lot of false diagnosis of latent TB in immigrants coming from countries that utilize the BCG

(*i say "supposed to" because if you look into these tests, or generally cepheid and their parent company danaher, you’d very quickly find that doctors without borders (MSF) and other global health activist organizations have been calling danaher out for pricegouging the xpert test cartridges, and profiteering from lifesaving tools that were developed with taxpayers’ money. after a ton of public pressure they dropped the price of standard MTB/RIF test and announced that they’re selling it at-cost (which is about $8 USD per test, but right now nobody knows how they got to that number so we’re all very patiently waiting for a little transparency there), but all the other testing cartridges (including not only for XDR-TB but also covid, HIV, ebola, & several others) are still way too expensive for the people who need them. the prices vary a bunch, but it’s all artificially inflated because the cartridges are basically identical and none are particularly difficult or expensive to manufacture)

sorry this has been very long lol i have a tuberculosis special interest and some burning rage in my heart over corporate greed. thank you and have a good day!

Please don’t apologise! This is super interesting to learn about (as well as something that people should definitely be more aware of). I really appreciate you taking the time to inform me, especially since I’m just a random shitposter who’s obsessed with fnaf

[kirancmi]

Tuberculosis Vaccine Market Is Estimated To Witness High Growth Owing To Increasing Research Funding

Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis. The disease generally affects the lungs but can also affect other parts of the body. The main symptoms are cough with sputum and blood sometimes, chest pains, weakness, weight loss, fever, and night sweats. Tuberculosis vaccines are given to prevent the disease or reduce its severity. Two main types of tuberculosis vaccines are available - Bacillus Calmette-Guérin (BCG) vaccine and others in clinical trials. BCG vaccine provides some protection against severe forms of tuberculosis in childhood. Different organizations provide research funding for the development of improved or new tuberculosis vaccines with better efficacy. The global tuberculosis vaccine market is estimated to be valued at US$ 149.67 Mn in 2023 and is expected to exhibit a CAGR of 21.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: Increasing research funding for tuberculosis vaccine development is a major driver fueling growth of the tuberculosis vaccine market. For instance, according to the World Health Organization (WHO), in 2017, total funding for tuberculosis research was US$ 778 million, with over half of research funded by public sources and the rest funded by private sources. Major public funders include National Institute of Allergy and Infectious Diseases (NIAID), European Commission, Department for International Development (UK), German Federal Ministry of Education and Research, and The Bill & Melinda Gates Foundation. Moreover, various initiatives such as European & Developing Countries Clinical Trials Partnership of European Union worth €700 million and TB Vaccine Initiative jointly funded by The Bill & Melinda Gates Foundation and UK's Wellcome Trust are further promoting research and development of tuberculosis vaccines. Such initiatives are expected to translate into pipeline products entering the market in coming years, thereby supporting market growth over the forecast period. SWOT Analysis Strength: Tuberculosis is one of the leading infectious killer diseases globally. The availability of effective TB vaccine can help save millions of lives each year. The existing vaccines are moderately effective and shows protection for around 10 years. Continuous research and development efforts are helping scientists develop more effective long lasting TB vaccines. Weakness: Developing an effective vaccine against a complex disease like TB is a challenging task which requires extensive research. The exact mechanism by which Mycobacterium tuberculosis infects the body is still not fully understood which poses difficulty in vaccine development. High development cost and lengthy clinical trials are some other weaknesses. Opportunity: According to WHO, tuberculosis remains one of the top 10 causes of death worldwide. The huge patient pool suffering from active and latent TB presents a massive market opportunity. Increasing government funding for TB research especially in high burden countries can boost vaccine development. Partnerships between private and public organizations is another opportunity area. Threats: Emergence of drug resistant TB strains is a major threat. Vaccines developed now may not remain effective against future strains in a rapidly evolving pathogen. Stringent regulatory norms for vaccine approval can increase uncertainty. Slow progress in TB diagnostic methods is also a challenge area. Key Takeaways The global tuberculosis vaccine market growth is expected to witness high growth over the forecast period supported by the increasing TB disease burden globally. According to WHO estimates, around 10 million new cases of TB emerged in 2021 reflecting the massive market potential.

Regionally Asia Pacific holds the highest potential owing to the large TB patient numbers. While preventive BCG vaccine offers partial protection, development of novel vaccines providing lifelong immunity remains the major focus.

Key players operating in the tuberculosis vaccine market are Fujitsu Limited, Mindtree Limited, IBM Corporation, Wipro Limited, Unisys Corporation, CenturyLink Inc., Virtustream Inc. and HCL Technologies Limited. These companies are engaged in developing novel vaccine candidates using advanced technologies. For instance, Fujitsu is working on a viral vector based vaccine targeting both active and latent TB infections. Similarly, Mindtree's artificial intelligence aided approaches can help accelerate vaccine screening. partners with academics and non-profits focused on neglected diseases to develop new tools in TB diagnosis and treatment. Further collaborative research is expected to result in an effective global vaccine to control the TB disease burden.

Get more insights on this topic: https://www.newsstatix.com/tuberculosis-vaccine-market-industry-insights-trends-tuberculosis-vaccine-market/

Explore more information on this topic, Please visit: https://wotpost.com/optical-transceivers-enabling-high-speed-data-transmission/

[addnoral]

Are You Suffering From Type-1 Diabetes? TB Vaccine May Help You

A vaccine primarily used for treating tuberculosis (TB) may be effective in reducing high blood sugar among people with Type – 1 diabetes, results from a clinical trial has revealed.The findings showed that, three years after receiving two administrations of the Bacillus Calmette-Guerin (BCG) vaccine four weeks apart, people with longstanding Type-1 diabetes showed an improvement in HbA1c —…

[techninja]

Bridging the Gap: Access and Distribution in the Human Tuberculosis Vaccine Market

Introduction

Tuberculosis (TB) remains a global health challenge, with millions of people affected each year. The development of an effective human tuberculosis vaccine has been a priority in the fight against this infectious disease. In recent years, significant advancements have been made in this field, offering hope for the control and eventual eradication of TB. This article explores the current state of the Human Tuberculosis Vaccine Market, including the challenges and opportunities it presents.

The Global Burden of Tuberculosis

Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis. It primarily affects the lungs but can also impact other parts of the body. Despite substantial progress in controlling the disease, TB remains a major public health threat, especially in developing countries. In 2019, approximately 10 million people fell ill with TB, and 1.4 million lost their lives due to the disease, according to the World Health Organization.

The Need for a TB Vaccine

The TB vaccine, known as the Bacille Calmette-Guérin (BCG) vaccine, has been in use for nearly a century. While it offers some protection against severe forms of TB in children, it has limited effectiveness against the more common and contagious forms of the disease in adults. The need for a more effective TB vaccine is clear, as drug-resistant strains of the bacterium are on the rise, making it even more challenging to control the spread of the disease.

Advancements in TB Vaccine Research

In recent years, there has been significant progress in TB vaccine research. Several vaccine candidates are in various stages of development and clinical trials. One notable candidate is the M72/AS01E vaccine, which showed promise in Phase 2 trials. This vaccine is intended for adults and aims to provide protection against TB infection.

Another promising candidate is VPM1002, which is a modified version of the existing BCG vaccine. It is being tested in clinical trials to evaluate its safety and efficacy. Additionally, other vaccines like H4:IC31 and ID93 + GLA-SE are under investigation, indicating a diverse range of approaches being explored in the quest for a TB vaccine.

Challenges in TB Vaccine Development

Developing a successful TB vaccine presents unique challenges. The bacterium's complex biology, the need for long-term protection, and the high variability of TB strains make vaccine development a difficult endeavor. Furthermore, the cost and time required for vaccine development and clinical testing are substantial hurdles.

Access and Distribution

Even with successful vaccine development, ensuring equitable access and distribution remains a significant challenge. TB predominantly affects low- and middle-income countries, where access to healthcare services and vaccines can be limited. Overcoming these barriers to vaccine distribution and affordability is crucial to effectively combat TB on a global scale.

Conclusion

The Human Tuberculosis Vaccine Market is at a critical juncture. Advancements in research and development offer hope for a more effective TB vaccine, which is desperately needed to combat this global health crisis. However, challenges in vaccine development, distribution, and accessibility must be addressed for meaningful progress to be made. The collaborative efforts of governments, pharmaceutical companies, and global health organizations are essential in the fight against tuberculosis. With continued dedication and innovation, a more effective TB vaccine may become a reality, reducing the global burden of this deadly disease and saving countless lives.

Few Other Promising Reports in Pharmaceutical Industry

Global Major Depressive Disorder (MDD) Treatment Market

Neuromodulation Devices Market

Mental Disorder Treatment Market

Serotonin Norepinephrine Inhibitor Market

[digitalmarketing923]

India Has Begun The Clinical Trial Of A New Tuberculosis Vaccine For Adults

India is home to 1/4th of the world’s tuberculosis burden, which has given the country an opportunity to make huge strides in public health by becoming a global leader in tuberculosis research. Taking this initiative, a vaccine trial was launched on 15th of July 2019 by the Indian Council of Medical Research (ICMR), to prevent occurrence of tuberculosis among close contacts of a tuberculosis patient who are at high risk of contracting the disease.

The new vaccine – Phase-III trials

The most famous BCG vaccine trial had been undertaken decades ago, after which a Phase-III trial is being conducted now for this new vaccine, to come up with the first tuberculosis vaccine for adults, as the BCG vaccine available and tested is only for newborns. This step is a stride towards prevention, which will help in decreasing the burden of the tuberculosis disease. After a detailed landscape analysis of the available lead vaccine candidates, two potential vaccine candidates VPM 1002 and MIP were shortlisted for being taken forward through the Phase-III trial in healthy household contacts of sputum smear positive tuberculosis patient. This clinical trial will evaluate the safety and efficacy of these two vaccines in a single trial, against a control group with no vaccine. The study would enroll 12,000 healthy household contacts of sputum smear positive tuberculosis cases that are at high risk of contracting the disease. These contacts would be from 7 sites in 6 states, namely Delhi, Orissa, Tamil Nadu, Karnataka, Maharashtra, and Telangana. The trial has begun at the first site, and will subsequently be initiated at other sites too, with a goal to complete the enrollment within 7-8 months.

What experts said

Balram Bhargava, Secretary at the Department of Health Research and Director General at ICMR, appreciated the Government’s support and researchers involved in the trial, at the launch of the vaccine’s clinical trial. He said that the clinical trials are needed in India to prove that the vaccine is safe and effective, and can provide protection to Indian populations, where the disease is endemic. The ultimate goal of this trial is to develop a vaccine that can prevent active tuberculosis and be a part of large campaigns aimed at eliminating the disease. The clinical study can thus help in achieving this goal and significantly advance the global fight against tuberculosis.

Rohit Sarin, Director at NITRD, said that this trial is a much awaited one, which is why he promised to provide complete support in timely completion of the procedure. In fact, every statutory regulatory body of India has approved this trial, as per the Indian regulatory guidelines.

You can also become an expert in the field of clinical research by undertaking a professional course of diploma in Clinical Research Bangalore at a reputed institute like Avigna Clinical Research Institute. This will help you achieve a certificate that will bring to you a good job in the field in top CROs, Bio-techs, and pharmaceutical companies.

[thebrokencrescent-blog]

📆 Oct 2019 📰 Protective Immunity and New Vaccines for Lyme Disease 🗞 PubMed Central

Live-attenuated mutant vaccines have been proven to be effective for immunization against several contagious infectious diseases. In terms of B. burgdorferi infection, live-attenuated flagella-less and p66 mutants of B. burgdorferi can elicit partial or fully protective immunity in mice [22]; these mutants are also more effective than killed bacteria.

Although such live mutants are incapable of establishing infection in mammalian hosts, this approach is unlikely to be used for human applications. Nevertheless, it could lead to identification of some individual targets with protective efficacy to develop new recombinant vaccine candidates; further, these mutants could be used to develop additional reservoir-targeted or other animal vaccines.

📆 Mar 2020 📰 Defining trained immunity and its role in health and disease 🗞 Nature Reviews

For a long time it was assumed that immunological memory was an exclusive hallmark of the adaptive immune response. However, a growing body of literature indicating that innate immune cells — and even tissue-resident stem cells — can show adaptive characteristics has challenged this dogma4,5,6,7,8. Greater protection against reinfection — a de facto immune memory function — has also been reported in plants and invertebrates9,10,11, which lack an adaptive immune system. This demonstrates that adaptation of host defence can occur on the basis of innate-like immune mechanisms. Moreover, certain infections and vaccinations can induce broad protection against other pathogens through innate immune mechanisms...

Many studies in mice have documented the existence of adaptive characteristics of innate immunity. Together, these studies demonstrated that training mice with different microbial ligands could protect against subsequent lethal infection in a non-specific manner. For example, treatment with the fungal ligand β-glucan protected against subsequent infection with Staphylococcus aureus24,25, while the peptidoglycan component muramyl dipeptide induced protection against Streptococcus pneumoniae and Toxoplasma gondii infections...

An increasing body of evidence suggests that trained immunity plays a critical role in humans. First, an extensive collection of epidemiological data argues that live vaccines such as the BCG vaccine, measles vaccine, smallpox vaccine and oral polio vaccine have beneficial, non-specific protective effects against infections other than the target diseases40,41,42,43,44,45,46,47 (for a review, see also ref.48). Subsequently, proof-of-principle trials with the BCG vaccine in adults23,49 and children50,51 demonstrated that this vaccine induces non-specific activation of innate immune cells.

Interestingly, both epidemiological and immunological studies have shown that the vaccine effects may last for months, but may also be modified or even reversed when a non-live vaccine is given52,53. Furthermore, BCG vaccination led to protection against microorganisms in models of controlled human infection, such as yellow fever54 or malaria55, and this was associated with an augmented proinflammatory activity of monocytes (Box 1). Second, certain infections, such as malaria, induce a state of hyper-responsiveness that is functionally equivalent to induction of trained immunity56,57,58.

Finally, there is evidence that BCG vaccination can induce antitumour immune effects leading to the prevention or treatment of malignancies such as bladder cancer59, melanoma60, leukaemia61 and lymphoma62. Notably, these anticancer effects of BCG seem to be dependent on its capacity to induce trained immunity in monocytes and macrophages63.

Trained immunity was initially shown to act through mature myeloid cells. Until recently this hypothesis resulted in a conundrum as mature myeloid cells, such as monocytes and DCs, in both mice and humans are short-lived, with an average half-life of 5–7 days100,101,102. Therefore, how trained immunity can be maintained in myeloid cells for several months, years and even decades41 remained unknown. More recent work has helped to resolve this issue by showing that trained immunity can occur in bone marrow progenitor cells (central trained immunity), as well as in blood monocytes and tissue macrophages (peripheral trained immunity) (Fig. 2).

In the past decade, a unique anamnestic response has been described in natural killer (NK) cells during cytomegalovirus infection. Experimental studies demonstrated that mouse and human NK cells possess adaptive immune characteristics following infection with mouse cytomegalovirus (MCMV) or human cytomegalovirus, respectively.

Mouse NK cells bearing the Ly49H receptor possess antigen specificity for MCMV-encoded glycoprotein m157 (refs74,75), can undergo clonal proliferation (as much as 104-fold expansion from a single NK cell clone)76,77 and persist during the contraction and memory phases similarly to CD8+ T cells78. On reinfection, these memory NK cells undergo a secondary expansion and can more rapidly degranulate and release cytokines, resulting in a more protective immune response against MCMV.

In human NK cells, the NKG2C receptor can mediate a similar function through recognition of human cytomegalovirus-encoded UL40 peptides presented on the non-classical MHC molecule HLA-E80,81.

Because these adaptive NK cell responses more closely resemble T cell responses than trained immunity in macrophages, yet occur in the absence of RAG-mediated antigen receptor gene rearrangement82, this unique NK cell response may represent an evolutionary bridge between the memory response of T cells and that of myeloid lineage cells78,83.

[manipalhospital1]

Can Vaccines Save You From Cancer?

The familiarity with the word “cancer” has increased in recent years. Cancer is a disease where abnormal cells grow uncontrollably and invade body tissue. Cancer prevalence, estimated in 2022, was found to be 14,61,427 (100.4 per 100,000). Thus, the probability of you developing cancer is one in nine in a lifetime. Amid all this, one way of dealing with certain cancers is vaccination.

The treatment of cancer via vaccines may or may not be the future but cancer prevention using vaccines is a reality. The basic rationale behind the cancer vaccines is the prevention of diseases that can lead to or have an association with developing into cancer in later stages.

Consult the best cancer hospital in Millers Road if you require cancer treatment-related services. 

How Do Cancer Vaccines Work?

Cancer vaccines are a type of immunotherapy designed to stimulate the immune system to recognize and target cancer cells. Unlike traditional vaccines that protect against infectious diseases, cancer vaccines aim to enhance your immune system's ability to identify and destroy cancer cells and can reduce the risk of developing cancer. The boost it gives immunity is also a major benefit the body achieves from it. The most well-known example is the HPV vaccine, which helps prevent cervical cancer caused by the human papillomavirus.

When cancer cells are already present in your body, therapeutic cancer vaccines may be effective. They work by stimulating your immune system to recognise and destroy cancer cells.

What are the Cancer Vaccines Available?

Human Papilloma Virus Vaccine (HPV)

HPV- Human Papillomavirus has long been related to sexually transmitted infections that can lead to certain types of cancers, such as cervical, vaginal, vulvar, and anal cancers. With the advent of HPV vaccination, research shows that the vaccine has delivered on its promise as the rate of these cancers has significantly reduced. Various randomised trials and population-based studies done by experts on HPV vaccination and its association with a decreased incidence of cervical cancer have proven to be significant.

It is recommended for both males and females between the ages of 11 and 12. It is also available for catch-up vaccination in individuals up to the age of 26. The vaccine is given in a series of shots over a few months to ensure optimal protection. The Indian government has initiated the HPV vaccine as a part of the immunisation program in schools on the cards for 2023 and the coming years.

Hepatitis B Vaccine (HBV)

The Hepatitis B virus affects the liver and causes end-stage liver damage. In chronic cases, the Hepatitis B virus stays silent in the liver, leading to liver cirrhosis and liver cancer in later stages. The introduction of the HBV vaccine has made a significant impact in preventing the transmission and consequences of this infectious disease.

The vaccine is administered through a standard schedule of three doses, with the second and third doses given at specific intervals after the initial dose. An accelerated schedule may be recommended for people with a higher risk of infection.

Therapeutic or treatment vaccines now in use include:

Bacille Calmette-Guerin (BCG) Vaccine

This vaccine was primarily made for the prevention of tuberculosis. However, later, its use in preventing bladder cancer was found. It is the most successful microbial immunotherapy for cancer in current use. Similar to Sipuleucel-T, BCG works by stimulating the immune system to recognize and attack cancer cells. However, unlike Sipuleucel-T, BCG does not require the use of a patient's white blood cells to work effectively.

First Cancer Vaccine: BCG was the first FDA-approved cancer prevention vaccine in 1990. It is the standard treatment for early-stage bladder cancer.

Sipuleucel-T

Sipuleucel-T is an immunotherapy designed to treat prostate cancer, specifically in advanced cases that are resistant to hormone therapy and have spread beyond the prostate. It's a customised treatment, with each dosage tailored to the patient.

Each patient's vaccine is created using these activated white blood cells. The treatment process generally takes six weeks and is delivered via three infusions every two weeks. Sipuleucel-T can be administered alone or in combination with other therapies.

Side Effects of Cancer Vaccines

Vaccines, as with all products regulated by the FDA, undergo trials before going onto the market for mass immunisation to rule out any severe side effects. The side effects of cancer vaccines depend on the individual's health status. Common side effects encountered are:

Fever

Body ache

Muscle fatigue

Headache

Chills

FDA-Approved Cancer Vaccines

The vaccines that have received FDA approval for cancer prevention are:

Hepatitis B vaccine.

Human PapillomaVirus (HPV) vaccine.

BCG Vaccine.

While cancer vaccines are still in the early stages of development and not yet widely available, they hold great promise for the future of cancer treatment in significantly preventing the occurrence of cancer worldwide.

Consult our best surgical oncologist in Millers Road if you require a cancer vaccine or other cancer-related services. 

[digimakacademy]

कोरोना से जंग में बुजुर्गों पर बीसीजी टीके के प्रभाव की टेस्टिंग को तमिलनाडु सरकार ने दी मंजूरी कोरोना वायरस (Coronavirus) के संक्रमण के खिलाफ जंग में बुजुर्गों पर बीसीजी के टीके (BCG vaccine) के प्रभाव के रिसर्च के लिए आईसीएमआर के टयूबर क्लोसिस इंस्टीट्यूट को टेस्टिंग की मंजूरी तमिलनाडु सरकार ने दी है।

[ramtracking]

Bharat Biotech starts clinical trials of TB jab [ BCG vaccine ]

Bharat Biotech starts clinical trials of TB jab [News Summary] The only vaccine in use today–BCG (Bacillus Calmette and Guerin)–is an attenuated variant of the bovine TB pathogen. This is more than a… India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world’s first Mycobacterium… World Tuberculosis (TB) Day is marked annually on 24 March, the…

[decentralvaccine]

An Old TB Vaccine Failed Against Covid 19

An old tuberculosis vaccine known to bolster the immune system did not prevent Covid infections among health care workers, scientists reported on Thursday.

But the trial was shorter and smaller than originally designed, and the investigators said that the results did not rule out other potential benefits associated with the vaccine, known as B.C.G. for bacille Calmette-Guerin.

The study, published in The New England Journal of Medicine, was the largest clinical trial of the vaccine’s potential to protect against Covid infections. B.C.G. was developed in the early 1900s to combat TB, but has since also been shown to confer protection against other illnesses, including respiratory diseases.

The trial of health care workers began in March 2020, during the early days of the pandemic, when no effective treatments for Covid were available and a new vaccine against the highly infectious disease seemed to be a remote fantasy. The hope was that the old vaccine might be repurposed to save lives.

https://www.nytimes.com/2023/04/26/health/bcg-vaccine-covid.html?smid=nytcore-ios-share&referringSource=articleShare

[intelligentliving]

An article recently released in Neuroscience News discusses the possible use of the Tuberculosis BCG vaccine to help protect against COVID-19. This drug is known for its protection against several respiratory viral infections. VPM1002 is based on the BCG vaccine, which has been around since the beginning of the 20th...